tradingkey.logo

tradingkey.logo
怜玢


Harvard Bioscience Inc

HBIO
りォッチリストに远加
8.050USD
+0.130+1.64%
終倀 09-23 16:00ET
36.31M時䟡総額
損倱額盎近12ヶ月PER

Harvard Bioscience Incに぀いお 䌁業名

Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.

Harvard Bioscience Inc プロフィヌル


䌁業コヌドHBIO
䌚瀟名Harvard Bioscience Inc
䞊堎日Oct 21, 2013
最高経営責任者「CEO」Duke (John D)
埓業員数330
蚌刞皮類Ordinary Share
決算期末Oct 21
本瀟所圚地84 October Hill Rd
郜垂HOLLISTON
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号01746-1371
電話番号15088938999
りェブサむトhttps://www.harvardbioscience.com/
䌁業コヌドHBIO
䞊堎日Oct 21, 2013
最高経営責任者「CEO」Duke (John D)

Harvard Bioscience Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Ms. Katherine Anne Eade, J.D.
Ms. Katherine Anne Eade, J.D.
Lead Independent Director
Lead Independent Director
58.67K
+28.22%
Ms. Katherine Anne Eade, J.D.
Ms. Katherine Anne Eade, J.D.
Lead Independent Director
Lead Independent Director
58.67K
+28.22%
Ms. Katherine Anne Eade, J.D.
Ms. Katherine Anne Eade, J.D.
Lead Independent Director
Lead Independent Director
58.67K
+28.22%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
27.56K
+60.08%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
27.56K
+60.08%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
27.56K
+60.08%
Mr. Stephen J. DeNelsky
Mr. Stephen J. DeNelsky
Independent Director
Independent Director
26.56K
+62.34%
Mr. Stephen J. DeNelsky
Mr. Stephen J. DeNelsky
Independent Director
Independent Director
26.56K
+62.34%
Mr. Stephen J. DeNelsky
Mr. Stephen J. DeNelsky
Independent Director
Independent Director
26.56K
+62.34%
Mr. Mark Frost
Mr. Mark Frost
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Ms. Katherine Anne Eade, J.D.
Ms. Katherine Anne Eade, J.D.
Lead Independent Director
Lead Independent Director
58.67K
+28.22%
Ms. Katherine Anne Eade, J.D.
Ms. Katherine Anne Eade, J.D.
Lead Independent Director
Lead Independent Director
58.67K
+28.22%
Ms. Katherine Anne Eade, J.D.
Ms. Katherine Anne Eade, J.D.
Lead Independent Director
Lead Independent Director
58.67K
+28.22%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
27.56K
+60.08%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
27.56K
+60.08%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
27.56K
+60.08%

よくある質問

Harvard Bioscience Incの䞊䜍5名の株䞻は誰ですか


Harvard Bioscience Incの䞊䜍5名の株䞻は以䞋のずおりです。Ms. Katherine Anne Eade, J.D.

Harvard Bioscience IncHBIOの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Harvard Bioscience Incの株匏を保有しおいる機関は201瀟あり、保有株匏の総垂堎䟡倀は玄2.44Mで、党䜓の54.17%を占めおいたす。2025Q4ず比范しお、機関の持ち株は-447956.00増加しおいたす。

Harvard Bioscience Incの最倧の収益源は䜕ですか


2026Q1においお、Instruments, equipment, software and accessories郚門がHarvard Bioscience Incにずっお最倧の収益を生み出しおおり、その金額は20.30Mで、党収益の89.34%を占めおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。